alendronate has been researched along with osteoprotegerin in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (38.10) | 29.6817 |
| 2010's | 25 (59.52) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong-Hwa, B; Kim, GS; Kim, YH | 1 |
| Caputo, JM; Price, PA; Williamson, MK | 1 |
| Bai, JZ; Chi, ZY; Huang, P; Ni, J; Wang, RD; Wang, Y; Yang, WJ; Yang, ZY | 1 |
| Goto, S; Kameyama, Y; Kawai, T; Kimura, M; Maeda, H; Miyazawa, K; Tabuchi, M | 1 |
| Dobnig, H; Fahrleitner-Pammer, A; Hofbauer, LC; Obermayer-Pietsch, B; Viereck, V | 1 |
| Asaba, Y; Harada, A; Hiramatsu, K; Ikeda, K; Ito, M; Katagiri, N; Kobayashi, T; Matsui, Y; Niida, S; Nimura, Y; Takewaka, T | 1 |
| Goltzman, D; Samadfam, R; Xia, Q | 2 |
| Kilby, M; McDonald, JM; Pan, G | 1 |
| Hargreaves, KM; Kitchens, JA; Schindler, WG; Schwartz, SA | 1 |
| Tankó, LB | 1 |
| Awad, HA; Bechtold, CD; Bukata, SV; Hock, C; Ito, H; Nakamura, T; O'Keefe, RJ; Proulx, ST; Schwarz, EM; Tsutsumi, R | 1 |
| Choi, HJ; Im, JA; Kim, SH | 1 |
| Brookler, K | 1 |
| Asuncion, F; Chiusaroli, R; Khatri, R; Kostenuik, P; Ohishi, M; Ominsky, M; Schipani, E; Thomas, C | 1 |
| He, JW; Hu, WW; Liu, YJ; Qin, YJ; Wang, C; Zhang, H; Zhang, ZL | 1 |
| Darmon, P; Molines, L; Raccah, D | 1 |
| Dabbous, MKh; Seshul, BA; Tipton, DA | 1 |
| Agholme, F; Aspenberg, P; Fahlgren, A; Magnusson, P | 1 |
| Alvarez, L; Combalia, A; Enjuanes, A; Guañabens, N; Martínez de Osaba, MJ; Monegal, A; Ozalla, D; Pares, A; Peris, P; Ruiz-Gaspà, S | 2 |
| Giner, M; Miranda, C; Montoya, MJ; Pérez-Cano, R; Rios, MJ; Vázquez, MA | 1 |
| Eslami, B; Glowacki, J; LeBoff, MS; Van Eekeren, I; Zhou, S | 1 |
| Chan, KM; Huang, P; Li, G; Tang, PF; Wang, Y | 1 |
| Kwon, YD; Lee, HW; Ohe, JY | 1 |
| Chiba, K; Hao, W; Hashimoto, K; Hoshi, H; Iwasaki, R; Kawasumi, M; Kimura, T; Kobayashi, T; Miyamoto, H; Miyamoto, K; Miyamoto, T; Miyauchi, Y; Morioka, H; Penninger, JM; Sato, Y; Suda, T; Toyama, Y; Yasuda, H; Yoshida, S | 1 |
| Jia, P; Li, Y; Liu, K; Wang, J; Wang, Z; Zhang, F | 1 |
| Chen, H; Deng, J; Dong, W; Feng, X; Liao, N; Qi, M | 1 |
| Arana-Chavez, VE; Bradaschia-Correa, V; Moreira, MM | 1 |
| Bohdanowicz-Pawlak, A; Szymczak, J | 2 |
| Gallagher, JC; Tella, SH | 1 |
| Cipriani, C; Colangelo, L; Minisola, S; Pepe, J; Piemonte, S; Romagnoli, E | 1 |
| Arana-Chavez, VE; Bradaschia-Correa, V; Ferreira, LB; Marques, ND; Moreira, MM | 1 |
| Aspenberg, P; Bernhardsson, M; Sandberg, O | 1 |
| Bonfietti, LH; De Almeida, J; Ervolino, E; Faleiros, PL; Fernandes, LA; Garcia, VG; Martins, TM; Novaes, VC; Theodoro, LH | 1 |
| Fu, WZ; He, JW; Wang, C; Zhang, ZL; Zheng, H | 1 |
| Fan, X; Liu, S; Liu, Y; Shao, J; Wang, Z; Yang, T; Ye, W; Zhang, Y | 1 |
| de Oliveira Puttini, I; Faverani, LP; Luvizuto, ER; Momesso, GAC; Okamoto, R; Ramalho-Ferreira, G | 1 |
| Elfiky, AA; Sayed, AA | 1 |
| Chen, X; Geng, T; Guo, H; Jin, Q; Sun, S; Yu, H; Zhang, S; Zheng, M | 1 |
| Feng, P; Shu, S; Zhao, F | 1 |
3 review(s) available for alendronate and osteoprotegerin
| Article | Year |
|---|---|
Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
Topics: Alendronate; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Cell Count; Denosumab; Humans; Osteoclasts; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B | 2007 |
Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment.
Topics: Alendronate; Arthropathy, Neurogenic; Biomarkers; Bone Density Conservation Agents; Calcitonin; Diabetic Foot; Diagnosis, Differential; Diphosphonates; Early Diagnosis; Foot Deformities, Acquired; Foot Injuries; Humans; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; RANK Ligand; Weight-Bearing | 2010 |
Prevention and treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Remodeling; Calcitonin; Denosumab; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Risk Factors; Selective Estrogen Receptor Modulators; Teriparatide | 2014 |
2 trial(s) available for alendronate and osteoprotegerin
| Article | Year |
|---|---|
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Etidronic Acid; Female; Hip; Humans; Osteocalcin; Osteoporosis; Osteoprotegerin; Postmenopause; Prospective Studies; RANK Ligand; Risedronic Acid | 2006 |
Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Topics: Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Collagen Type I; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Osteoprotegerin; Peptides | 2008 |
37 other study(ies) available for alendronate and osteoprotegerin
| Article | Year |
|---|---|
Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
Topics: Alendronate; Animals; Bone Resorption; Carrier Proteins; Cells, Cultured; Diphosphonates; Gene Expression Regulation; Glycoproteins; Membrane Glycoproteins; Mice; Mice, Inbred ICR; Osteoblasts; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction | 2002 |
Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment.
Topics: Alendronate; alpha-Fetoproteins; Animals; Bone and Bones; Bone Remodeling; Bone Resorption; Calcitonin; Calcium; Calcium-Binding Proteins; Disease Models, Animal; Etidronic Acid; Extracellular Matrix Proteins; Feeding Behavior; Glycoproteins; Humans; Injections; Male; Matrix Gla Protein; Osteoprotegerin; Phosphates; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Time Factors | 2002 |
[In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast].
Topics: Alendronate; Animals; Drug Synergism; Humans; In Vitro Techniques; Mice; Mice, Inbred Strains; Osteoclasts; Osteoprotegerin; Pichia; Recombinant Proteins | 2005 |
Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone Morphogenetic Proteins; Bone Resorption; Cattle; Chondrogenesis; Disease Models, Animal; Drug Synergism; Female; Glycoproteins; Injections, Subcutaneous; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Ossification, Heterotopic; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Osteoprotegerin; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2005 |
Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption.
Topics: Aged; Aged, 80 and over; Alendronate; Amino Acids; Animals; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Female; gamma-Glutamyltransferase; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Osteoporosis, Postmenopausal; Osteoprotegerin; Peptides | 2006 |
Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice.
Topics: Alendronate; Animals; Bone and Bones; Female; Femur; Mice; Mice, Inbred C57BL; Osteoprotegerin; Ovariectomy; Parathyroid Hormone; Spine | 2007 |
Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors.
Topics: Alendronate; Animals; Apoptosis; Cell Differentiation; Didanosine; Humans; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; Osteoclasts; Osteoprotegerin; RANK Ligand; Reverse Transcriptase Inhibitors; Zidovudine | 2006 |
Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Drug Therapy, Combination; Female; Gene Expression Regulation; Metabolism; Mice; Mice, Inbred C57BL; Osteoclasts; Osteoprotegerin; Ovariectomy; Parathyroid Hormone | 2007 |
Iontophoresis significantly increases the trans-dentinal delivery of osteoprotegerin, alendronate, and calcitonin.
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Dentin; Dentin Permeability; Diffusion; Electrochemistry; Humans; Iontophoresis; Osteoprotegerin; Time Factors; Tooth Cervix; Tooth Resorption | 2007 |
Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Image Processing, Computer-Assisted; Imidazoles; Mice; Osteoclasts; Osteolysis; Osteoprotegerin; Polyethylene; Prosthesis Failure; Skull; Surface Properties; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined Modality Therapy; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ear, Inner; Ear, Middle; Etidronic Acid; Follow-Up Studies; Hearing Aids; Hearing Loss, Sensorineural; Humans; Male; Middle Aged; Osteoclasts; Osteoprotegerin; Otosclerosis; Risedronic Acid; Speech Discrimination Tests; Speech Reception Threshold Test; Stapes Surgery; Tinnitus | 2008 |
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Humans; Hyperparathyroidism; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Porosity; Primary Myelofibrosis; Receptor, Parathyroid Hormone, Type 1; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
[Osteoprotegerin gene polymorphism and therapeutic response to alendronate in postmenopausal women with osteoporosis].
Topics: Aged; Alendronate; Alleles; Bone Density; Female; Genotype; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; Polymorphism, Genetic | 2009 |
Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6.
Topics: Alendronate; Analysis of Variance; Bone Density Conservation Agents; Bone Remodeling; Cells, Cultured; Diphosphonates; Fibroblasts; Gingiva; Humans; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Necrosis; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Statistics, Nonparametric | 2011 |
Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Density Conservation Agents; Bone Plates; Bone Resorption; Immunohistochemistry; Isoenzymes; Male; Osteoprotegerin; Prostheses and Implants; RANK Ligand; Rats; Rats, Sprague-Dawley; Tartrate-Resistant Acid Phosphatase; Tibia | 2011 |
The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.
Topics: Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Cell Differentiation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression; Humans; Osteoblasts; Osteoprotegerin; RANK Ligand; RNA, Messenger; Vitamin D | 2010 |
The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Cell Differentiation; Cell Survival; Cells, Cultured; Gene Expression Regulation; Humans; Middle Aged; Osmolar Concentration; Osteoblasts; Osteocalcin; Osteoporosis; Osteoprotegerin; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Vitamin D | 2010 |
Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Cells, Cultured; Estradiol; Female; Humans; Male; Middle Aged; Osteoarthritis; Osteoblasts; Osteoporosis, Postmenopausal; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; RNA, Messenger | 2011 |
Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate.
Topics: Aged, 80 and over; Alendronate; Bone Marrow Cells; Case-Control Studies; Cell Differentiation; Diphosphonates; Female; Gene Expression Regulation; Humans; Orthopedics; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Stem Cells | 2011 |
Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Drug Therapy, Combination; Female; Models, Animal; Osteoprotegerin; Ovariectomy; RANK Ligand; Rats; Rats, Sprague-Dawley | 2011 |
Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Culture Techniques; Cell Differentiation; Culture Media; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); Humans; Macrophage Colony-Stimulating Factor; Male; Mesenchymal Stem Cells; Osteoblasts; Osteoclasts; Osteogenesis; Osteoprotegerin; Pamidronate; Real-Time Polymerase Chain Reaction; Time Factors; Young Adult | 2012 |
Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Marrow; Cells, Cultured; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Mice; Mice, Transgenic; Osteoclasts; Osteopetrosis; Osteoprotegerin; Proto-Oncogene Proteins c-fos; RANK Ligand; Stem Cell Niche | 2011 |
The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat.
Topics: Alendronate; Animals; Aorta; Calcinosis; Calcium; Gene Expression Regulation; Male; Osteopontin; Osteoprotegerin; Rats; Rats, Sprague-Dawley | 2012 |
[Effect of alendronate on expressions of osteoprotegerin and receptor activator of nuclear factor κB ligand in mouse osteoblasts].
Topics: Alendronate; Animals; Cells, Cultured; Mice; Mice, Inbred BALB C; Osteoblasts; Osteoprotegerin; RANK Ligand | 2012 |
Reduced RANKL expression impedes osteoclast activation and tooth eruption in alendronate-treated rats.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Dental Sac; Isoenzymes; Osteoclasts; Osteoprotegerin; RANK Ligand; Rats; Rats, Wistar; Receptor Activator of Nuclear Factor-kappa B; Tartrate-Resistant Acid Phosphatase; Tooth Eruption | 2013 |
Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Case-Control Studies; Female; Humans; Hyperparathyroidism, Primary; Male; Osteoprotegerin; Parathyroidectomy; RANK Ligand | 2013 |
Osteoprotegerin serum levels in primary hyperparathyroidism and changes following surgery.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Female; Humans; Hyperparathyroidism, Primary; Male; Osteoprotegerin; RANK Ligand | 2014 |
Osteoprotegerin in primary hyperparathyroidism.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Female; Humans; Hyperparathyroidism, Primary; Male; Osteoprotegerin; RANK Ligand | 2014 |
Ultrastructural and immunohistochemical study of the effect of sodium alendronate in the progression of experimental periodontitis in rats.
Topics: Alendronate; Alveolar Process; Animals; Dental Papilla; Disease Progression; Gingiva; Male; Microscopy; Microscopy, Electron, Transmission; Osteoprotegerin; Periodontitis; RANK Ligand; Rats; Rats, Wistar | 2014 |
Anti-RANKL treatment improves screw fixation in cancellous bone in rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Fracture Healing; Male; Osteoprotegerin; RANK Ligand; Rats; Rats, Sprague-Dawley; Tibia; Tibial Fractures | 2015 |
Adjuvant Therapy With Sodium Alendronate for the Treatment of Experimental Periodontitis in Rats.
Topics: Alendronate; Alveolar Process; Animals; Apoptosis; Bone Density Conservation Agents; Caspase 3; Combined Modality Therapy; Dental Scaling; Osteoclasts; Osteocytes; Osteoprotegerin; Periodontitis; RANK Ligand; Rats; Rats, Wistar; Root Planing; Tartrate-Resistant Acid Phosphatase; Therapeutic Irrigation; Time Factors | 2015 |
OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
Topics: Alendronate; Bone Density; Bone Diseases, Metabolic; China; Female; Femur Neck; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Osteoprotegerin; Pelvic Bones; Polymorphism, Single Nucleotide; Postmenopause; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Treatment Outcome | 2016 |
Aqueous extract of pomegranate seed attenuates glucocorticoid-induced bone loss and hypercalciuria in mice: A comparative study with alendronate.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Duodenum; Glucocorticoids; Hypercalciuria; Kidney; Lythraceae; Male; Membrane Transport Proteins; Mice, Inbred C57BL; Osteoprotegerin; Phytotherapy; Plant Extracts; RANK Ligand; Receptors, Calcium-Sensing; Seeds; Tartrate-Resistant Acid Phosphatase; Testosterone; Tibia; Water | 2016 |
Effect of antiresorptive drugs in the alveolar bone healing. A histometric and immunohistochemical study in ovariectomized rats.
Topics: Alendronate; Alveolar Process; Animals; Bone Density Conservation Agents; Female; Immunohistochemistry; Osteocalcin; Osteogenesis; Osteoprotegerin; Ovariectomy; Raloxifene Hydrochloride; RANK Ligand; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase; Wound Healing | 2017 |
In silico estrogen-like activity and in vivo osteoclastogenesis inhibitory effect of Cicer arietinum extract.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium-Binding Proteins; Cicer; Disease Models, Animal; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation; Genistein; Humans; Isoflavones; Membrane Glycoproteins; Molecular Docking Simulation; Osteogenesis; Osteoporosis; Osteoprotegerin; Ovariectomy; Phytoestrogens; Phytotherapy; Protein Structure, Secondary; RANK Ligand; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Peptide | 2018 |
Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice.
Topics: Aged; Alendronate; Animals; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Female; Humans; Mice; Osteocalcin; Osteoclasts; Osteogenesis; Osteolysis; Osteoporosis; Osteoprotegerin; Prosthesis Failure; Thiophenes | 2018 |
Anti-osteoporosis Effect of Fisetin against Ovariectomy Induced Osteoporosis in Rats: In silico, in vitro and in vivo Activity.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Density; Cell Line; Cell Proliferation; Cytokines; Disease Models, Animal; Female; Flavonols; Humans; Osteoporosis, Postmenopausal; Osteoprotegerin; Ovariectomy; Phytotherapy; RANK Ligand; Rats, Sprague-Dawley; Receptors, Calcitriol; Receptors, Estrogen | 2022 |